Sugi Predict

Sugi Predict / Targets / JMJD6

JMJD6

Bifunctional arginine demethylase and lysyl-hydroxylase JMJD6 · Q6NYC1 · JMJD6 on Sugi Atlas →

8,203 patent compounds predicted against JMJD6, 3,625 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL937382 SCHEMBL937382 0.57 14/20
SCHEMBL811785 SCHEMBL811785 0.76 13/20
SCHEMBL1333711 SCHEMBL1333711 0.68 13/20
SCHEMBL2688111 SCHEMBL2688111 0.68 13/20
SCHEMBL3442381 SCHEMBL3442381 0.61 13/20
SCHEMBL114066 SCHEMBL114066 0.60 12/20
SCHEMBL3442915 SCHEMBL3442915 0.50 11/20
SCHEMBL3167342 SCHEMBL3167342 0.55 10/20
SCHEMBL939441 SCHEMBL939441 0.54 10/20
SCHEMBL3442274 SCHEMBL3442274 0.53 10/20
SCHEMBL3442954 SCHEMBL3442954 0.53 10/20
SCHEMBL1985842 SCHEMBL1985842 0.52 10/20
SCHEMBL2301563 SCHEMBL2301563 0.65 9/20
SCHEMBL1993315 SCHEMBL1993315 0.50 9/20
SCHEMBL70279 SCHEMBL70279 0.73 8/20
SCHEMBL1984498 SCHEMBL1984498 0.51 8/20
SCHEMBL1982626 SCHEMBL1982626 0.49 7/20
SCHEMBL2664133 SCHEMBL2664133 0.49 7/20
SCHEMBL1982810 SCHEMBL1982810 0.48 7/20
SCHEMBL2668105 SCHEMBL2668105 0.42 7/20

Clinical trials — most relevant to JMJD6 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Phase 1/ Phase 2 Study to Assess Safety and Efficacy of Orally Administered JBI-802 in Subjects With Myeloproliferative Neoplasms (MPN) and Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN) With Thrombocytosis PHASE1/PHASE2RECRUITING
Phase I/II Study of Decitabine and Valproic Acid in Relapsed/Refractory Leukemia or Myelodysplastic Syndromes PHASE1/PHASE2COMPLETED
Trial of the Histone-Deacetylase Inhibitor ITF2357 Followed by Mechlorethamine in Relapsed/Refractory Hodgkin's Lymphoma PHASE1/PHASE2COMPLETED
Safety and Efficacy of BMS-986504 in Unresectable Malignant Peripheral Nerve Sheath Tumor PHASE1/PHASE2NOT_YET_RECRUITING
Study of the Beach Regimen on Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) PHASE2ACTIVE_NOT_RECRUITING
IDH2 (AG 221) Inhibitor in Patients With IDH2 Mutated Myelodysplastic Syndrome PHASE2ACTIVE_NOT_RECRUITING
IDH1 (AG 120) Inhibitor in Patients With IDH1 Mutated Myelodysplastic Syndrome PHASE2ACTIVE_NOT_RECRUITING
Phase I Trial of 4'-Thio-2'-Deoxycytidine (TdCyd) in Patients With Advanced Solid Tumors PHASE1COMPLETED
5-aza-4'-Thio-2'-Deoxycytidine (Aza-TdC) in People With Advanced Solid Tumors PHASE1RECRUITING
Study of Cytolytic Viral Activation Therapy (CVAT) for Recurrent/Metastatic Nasopharyngeal Carcinoma PHASE1UNKNOWN
Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome PHASE1COMPLETED
Safety and Pharmacokinetic Profile of CKD-581 PHASE1COMPLETED
PHF19 Gene Expression and EZH2 Gene Deletion in Acute Myeloid Leukemia nanUNKNOWN
The Molecular Pathogenesis Study of Cataract nanUNKNOWN
Lysine-specific Demethylase 1 and Salt-sensitivity in Humans nanACTIVE_NOT_RECRUITING
Investigation of Methylation of EGFR in the Response of the Cetuximab in Metastatic Colorectal Cancer Patients nanCOMPLETED
Studying The Role of Key Epigenetic Mediators in Breast Cancer Patients nanRECRUITING
Model to Predict pCR and IrAEs in Early Stage Non-small Cell Lung Cancer nanUNKNOWN
Expression of TET1 Gene in Acute Leukaemia nanUNKNOWN
Mechanisms of Immune Deficiency nanUNKNOWN
The Danish TURNER Cryopreservation Study nanRECRUITING
The Clinical Value of the Nitric Oxide System Components in Asthma and COPD nanUNKNOWN
Target of Suv420h1/2 in Hepatocytes nanRECRUITING
Adenosylmethionine Metabolism in Human Inflammation nanUNKNOWN
X-chromosome Inactivation, Epigenetics and the Transcriptome nanCOMPLETED
DNA Methylation and Perioperative Pain Treatment nanCOMPLETED
Impact of a Monoamine Oxidase Inhibitor on the Phenotype of Blood Mononucleated Cells in Patients With COVID-19 nanCOMPLETED
CMOP Regimen and Chidamide in the Treatment of Newly Diagnosed Peripheral T-cell Lymphoma nanUNKNOWN
Epitranscriptomic Blood Biomarkers for Coronary Artery Disease - A Prospective Cohort Study (IHD-EPITRAN) nanUNKNOWN
Effect of Arginine and Glutamine on Radiation-induced Oral Mucositis: a Trible Blinded Randomized Controlled Clinical Trial nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a JMJD6 binder may also engage these)

ProteinNameSimilarity
Q5R6G2 — 1.000 Q5R6G2 →
Q58DS6 — 1.000 Q58DS6 →
Q5ZMK5 — 1.000 Q5ZMK5 →
Q6AYK2 — 1.000 Q6AYK2 →
Q9ERI5 — 1.000 Q9ERI5 →
Q6PFM0 — 0.997 Q6PFM0 →
Q6GND3 — 0.997 Q6GND3 →
Q9VD28 — 0.994 Q9VD28 →
Q7ZX37 — 0.994 Q7ZX37 →
Q9GYI4 — 0.994 Q9GYI4 →
Q6Q4H1 — 0.993 Q6Q4H1 →
Q623U2 — 0.993 Q623U2 →
Q6C423 — 0.982 Q6C423 →
KDM5B Lysine-specific demethylase 5B 0.980 landscape →
B4Q068 — 0.979 B4Q068 →
Q5XHF8 — 0.979 Q5XHF8 →
Q9V333 — 0.978 Q9V333 →
Q7K4H4 — 0.978 Q7K4H4 →
B4GUZ2 — 0.978 B4GUZ2 →
B3NU20 — 0.978 B3NU20 →
F4J8C6 — 0.977 F4J8C6 →
Q5F3R2 — 0.977 Q5F3R2 →
Q9M9E8 — 0.977 Q9M9E8 →
KDM5D Lysine-specific demethylase 5D 0.976 landscape →
O23461 — 0.976 O23461 →
Q8MJ26 — 0.976 Q8MJ26 →
B6ZLK2 — 0.976 B6ZLK2 →
B4NP88 — 0.976 B4NP88 →
A3KP59 — 0.976 A3KP59 →
Q84WW3 — 0.976 Q84WW3 →